These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33808404)

  • 61. Liraglutide Decreases Hepatic Inflammation and Injury in Advanced Lean Non-Alcoholic Steatohepatitis.
    Ipsen DH; Rolin B; Rakipovski G; Skovsted GF; Madsen A; Kolstrup S; Schou-Pedersen AM; Skat-Rørdam J; Lykkesfeldt J; Tveden-Nyborg P
    Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):704-713. PubMed ID: 29953740
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Dulaglutide Protects Mice against Diabetic Sarcopenia-Mediated Muscle Injury by Inhibiting Inflammation and Regulating the Differentiation of Myoblasts.
    Deng F; Wu W; Fan X; Zhong X; Wang N; Wang Y; Pan T; Du Y
    Int J Endocrinol; 2023; 2023():9926462. PubMed ID: 37584041
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A Case of Dulaglutide-Induced Acute Interstitial Nephritis After Many Years of Treatment With an Alternate GLP-1 Receptor Agonist.
    Komala MG; Renthawa J
    Clin Diabetes; 2022; 40(4):508-510. PubMed ID: 36385974
    [No Abstract]   [Full Text] [Related]  

  • 64. Retraction notice to "A feasibility study of the combination of intranasal insulin with dulaglutide for cognition in older adults with metabolic syndrome at high dementia risk- Study rationale and design" [Mech. Ageing Dev. 213 (2023) 111825].
    Davidy T; Yore I; Cukierman-Yaffe T; Ravona-Springer R; Livny A; Lesman-Segev OH; Azuri Y; Carmichael O; Kapogiannis D; Zetterberg H; Lin H; Sano M; Beeri MS
    Mech Ageing Dev; 2024 Jun; 219():111937. PubMed ID: 38702256
    [No Abstract]   [Full Text] [Related]  

  • 65. Experience with dulaglutide in a diabetic and obese patient on incremental peritoneal dialysis.
    González Sanchidrián S; Gallego Domínguez S; Jiménez Mayor E; Labrador Gómez PJ; Deira Lorenzo J
    Nefrologia (Engl Ed); 2024 Jun; ():. PubMed ID: 38871561
    [No Abstract]   [Full Text] [Related]  

  • 66. Response to "Experience with dulaglutide in an obese diabetic patient on incremental peritoneal dialysis". Response to related letter.
    De La Flor JC; Moral E; Deira J; Monzón T; Valga F; Albarracín C; Rodeles M
    Nefrologia (Engl Ed); 2024 Jun; ():. PubMed ID: 38862303
    [No Abstract]   [Full Text] [Related]  

  • 67. Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data.
    Arai T; Atsukawa M; Tsubota A; Mikami S; Ono H; Kawano T; Yoshida Y; Tanabe T; Okubo T; Hayama K; Nakagawa-Iwashita A; Itokawa N; Kondo C; Kaneko K; Emoto N; Nagao M; Inagaki K; Fukuda I; Sugihara H; Iwakiri K
    Ther Adv Endocrinol Metab; 2021; 12():20420188211000243. PubMed ID: 33815743
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta- Analysis of Randomized Placebo-Controlled Trials.
    Li D; Liu Y; Hidru TH; Yang X; Wang Y; Chen C; Li KHC; Tang Y; Wei Y; Tse G; Xia Y
    Front Endocrinol (Lausanne); 2021; 12():619586. PubMed ID: 33815278
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Retracted: Effect of dipeptidyl peptidase-4 inhibitors on the progression of atherosclerosis in patients with type 2 diabetes mellitus: A meta-analysis of randomised controlled trials.
    Shi H; Peng M; Liu Y; Kan Z; Li W; Yang T
    Int J Clin Pract; 2021 Dec; 75(12):e14213. PubMed ID: 33819377
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cardiac substrate utilization in heart failure: Where is the relevance of SGLT2 inhibition?
    Mann PA; Lehrke M
    J Thorac Cardiovasc Surg; 2022 Sep; 164(3):895-899. PubMed ID: 33812679
    [No Abstract]   [Full Text] [Related]  

  • 71. Commentary: SGLT2 inhibitors reduce mortality and heart failure in patients with type 2 diabetes mellitus-is metabolic reprogramming the mechanism for these favorable outcomes?
    Lazar HL
    J Thorac Cardiovasc Surg; 2022 Sep; 164(3):901-904. PubMed ID: 33812677
    [No Abstract]   [Full Text] [Related]  

  • 72. Angiotensin II up-regulates sodium-glucose co-transporter 2 expression and SGLT2 inhibitor attenuates Ang II-induced hypertensive renal injury in mice.
    Miyata KN; Lo CS; Zhao S; Liao MC; Pang Y; Chang SY; Peng J; Kretzler M; Filep JG; Ingelfinger JR; Zhang SL; Chan JSD
    Clin Sci (Lond); 2021 Apr; 135(7):943-961. PubMed ID: 33822013
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia.
    Ji Q; Ji L; Mu Y; Zhao J; Zinman B; Wanner C; George JT; Zwiener I; Ueki K; Yokote K; Ogawa W; Johansen OE
    Diabetes Obes Metab; 2021 Aug; 23(8):1886-1891. PubMed ID: 33950573
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease.
    Ehlers LH; Lamotte M; Monteiro S; Sandgaard S; Holmgaard P; Frary EC; Ejskjaer N
    Diabetes Ther; 2021 May; 12(5):1523-1534. PubMed ID: 33856655
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Overexpression of Nrf2 in Renal Proximal Tubular Cells Stimulates Sodium-Glucose Cotransporter 2 Expression and Exacerbates Dysglycemia and Kidney Injury in Diabetic Mice.
    Zhao S; Lo CS; Miyata KN; Ghosh A; Zhao XP; Chenier I; Cailhier JF; Ethier J; Lattouf JB; Filep JG; Ingelfinger JR; Zhang SL; Chan JSD
    Diabetes; 2021 Jun; 70(6):1388-1403. PubMed ID: 33820760
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The Effect of Sodium Glucose Cotransporter 2 Inhibitors From a Human Genetic Perspective.
    Liu XZ; Zhang H
    Front Genet; 2021; 12():658012. PubMed ID: 33815487
    [No Abstract]   [Full Text] [Related]  

  • 77. Role of newer antidiabetic drugs on cardiovascular prevention and heart failure.
    Rojas-Velázquez JM; Giralt-Herrera A; Leiva-Enríquez J; Leiva-Enríquez J
    Clin Investig Arterioscler; 2021; 33(6):314-322. PubMed ID: 33820673
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The safety outcomes of sodium-glucose cotransporter 2 inhibitors in patients with different renal function: A systematic review and meta-analysis.
    Bai Y; Jin J; Zhou W; Zhang S; Xu J
    Nutr Metab Cardiovasc Dis; 2021 May; 31(5):1365-1374. PubMed ID: 33812735
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
    Gawrieh S; Noureddin M; Loo N; Mohseni R; Awasty V; Cusi K; Kowdley KV; Lai M; Schiff E; Parmar D; Patel P; Chalasani N
    Hepatology; 2021 Oct; 74(4):1809-1824. PubMed ID: 33811367
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH.
    Perakakis N; Chrysafi P; Feigh M; Veidal SS; Mantzoros CS
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34199317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.